» Articles » PMID: 36979690

HDL-Based Therapy: Vascular Protection at All Stages

Overview
Journal Biomedicines
Date 2023 Mar 29
PMID 36979690
Authors
Affiliations
Soon will be listed here.
Abstract

It is known that lipid metabolism disorders are involved in a wide range of pathologies. These pathologies include cardiovascular, metabolic, neurodegenerative diseases, and even cancer. All these diseases lead to serious health consequences, which makes it impossible to ignore them. Unfortunately, these diseases most often have a complex pathogenesis, which makes it difficult to study them and, in particular, diagnose and treat them. HDL is an important part of lipid metabolism, performing many functions under normal conditions. One of such functions is the maintaining of the reverse cholesterol transport. These functions are also implicated in pathology development. Thus, HDL contributes to vascular protection, which has been demonstrated in various conditions: Alzheimer's disease, atherosclerosis, etc. Many studies have shown that serum levels of HDL cholesterol correlate negatively with CV risk. With these data, HDL-C is a promising therapeutic target. In this manuscript, we reviewed HDL-based therapeutic strategies that are currently being used or may be developed soon.

Citing Articles

The two coin sides of bacterial extracellular membrane nanovesicles: atherosclerosis trigger or remedy.

Lusta K, Churov A, Beloyartsev D, Golovyuk A, Lee A, Sukhorukov V Discov Nano. 2024; 19(1):179.

PMID: 39532781 PMC: 11557815. DOI: 10.1186/s11671-024-04149-8.


The possible connection between neutrophil-to-high-density lipoprotein ratio and cerebral perfusion in clinically established corticobasal syndrome: a pilot study.

Chunowski P, Migda B, Madetko-Alster N, Migda A, Kutylowski M, Krolicki L Front Neurol. 2024; 15:1464524.

PMID: 39421569 PMC: 11484016. DOI: 10.3389/fneur.2024.1464524.


Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study.

Tao H, Yu Z, Dong Y, Liu L, Peng L, Chen X Front Immunol. 2023; 14:1160312.

PMID: 37350960 PMC: 10282130. DOI: 10.3389/fimmu.2023.1160312.

References
1.
Kallend D, Reijers J, Bellibas S, Bobillier A, Kempen H, Burggraaf J . A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. Eur Heart J Cardiovasc Pharmacother. 2016; 2(1):23-9. PMC: 4900740. DOI: 10.1093/ehjcvp/pvv041. View

2.
Pandrangi S, Chittineedi P, Chikati R, Neira Mosquera J, Sanchez Llaguno S, Mohiddin G . Role of Lipoproteins in the Pathophysiology of Breast Cancer. Membranes (Basel). 2022; 12(5). PMC: 9145187. DOI: 10.3390/membranes12050532. View

3.
Feng H, Wang M, Wu C, Yu J, Wang D, Ma J . High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in lung adenocarcinoma: A STROBE compliant article. Medicine (Baltimore). 2018; 97(13):e0203. PMC: 5895397. DOI: 10.1097/MD.0000000000010203. View

4.
Gille A, DAndrea D, Tortorici M, Hartel G, Wright S . CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients. Arterioscler Thromb Vasc Biol. 2018; 38(4):953-963. PMC: 5895137. DOI: 10.1161/ATVBAHA.118.310538. View

5.
Button E, Robert J, Caffrey T, Fan J, Zhao W, Wellington C . HDL from an Alzheimer's disease perspective. Curr Opin Lipidol. 2019; 30(3):224-234. PMC: 6530968. DOI: 10.1097/MOL.0000000000000604. View